Canine Protein-Losing Nephropathy: Clinical Decisions

Bottom line

Confirm persistent renal protein loss before labeling a dog with protein-losing nephropathy (PLN), and separate antiproteinuric care from the decision to immunosuppress. A high urine protein:creatinine ratio (UPC) does not identify an immune mechanism. [1] The useful treatment plan links proteinuria, renal function, blood pressure and albumin to a decision that can be reassessed.

Localize the proteinuria before treating the label

Proteinuria may be prerenal, renal or postrenal. Renal causes include glomerular, tubular and inflammatory disease. Urinary infection, inflammation, gross hematuria and overflow proteinuria can complicate interpretation; UPC ranges overlap between renal lesions. Do not infer biopsy findings from the size of the UPC alone. [1]

Review the original urinalysis, sediment, collection circumstances, culture where indicated, and serial results. Ask what changed between samples and whether the current measurement represents the same process. Put hydration, blood pressure, creatinine, albumin and medication exposure alongside the urine results rather than interpreting each in isolation.

When low albumin is the presenting finding, the canine protein-losing enteropathy workup addresses an alternative site of loss. Do not carry an intestinal treatment plan into a renal case merely because both have hypoalbuminemia.

Look for a treatable association and decide whether biopsy changes care

Current IRIS recommendations include investigating persistent proteinuria even in nonazotemic dogs, seeking associated treatable disease, and considering renal biopsy in appropriate stage 1–3 patients. [2]

Build exposure-directed investigation around the actual patient. The canine leptospirosis diagnostic hub addresses that specific infectious differential; a positive screening result requires clinical interpretation and does not establish the cause of every proteinuric presentation.

Before biopsy, name the decision it would change: whether to immunosuppress, whether an inherited or deposit disease is more likely, or whether advanced irreversible injury changes expectations. The consensus advises against biopsy when contraindications cannot be mitigated, when the result will not alter treatment or outcome, and in stage 4 CKD. Relevant contraindications include uncontrolled hypertension, coagulopathy and renal infection. [1]

Arrange appropriate tissue handling and specialist interpretation before sampling. A specimen that cannot answer the intended question should not be treated as definitive reassurance.

Establish antiproteinuric care with a safety endpoint

IRIS recommends an angiotensin receptor blocker (ARB) and a clinical kidney diet for proteinuric dogs, with treatment aiming to reduce proteinuria without harm. ACE inhibitor or ARB use is contraindicated during clinical dehydration or hypovolemia. Combination renin–angiotensin system blockade requires particular caution and preferably nephrology consultation. [2]

The canine randomized double-masked trial compared telmisartan with enalapril in persistent renal proteinuria. Telmisartan produced a greater early reduction in UPC; later comparisons involved selected nonresponders and treatment escalation. This was an antiproteinuric efficacy study, not evidence of superior survival or a universal choice across acute renal disease. Combination therapy caused clinically relevant azotemia in some dogs. [3]

Before changing treatment, specify what would count as benefit and what would count as intolerance. A falling UPC should not distract from worsening renal function, poor intake or a new volume problem. Reassess the entire treatment and hydration context before escalating or combining drugs; repeated prescriptions without paired safety measurements are not a response assessment.

Reserve immunosuppression for a defined rationale

The established-pathology consensus supports immunosuppression for severe, persistent or progressive glomerular disease with biopsy-supported active immune pathogenesis and no contraindication. Electron microscopy and immunofluorescence provide important evidence, but residual deposits or remodeling may reflect previous rather than ongoing immune injury. A nephropathologist should interpret the pattern and activity. [4]

When biopsy is unavailable, the separate consensus does not endorse automatic empirical steroids. It advises against immunosuppression when protein loss is not definitively glomerular, a contraindication exists, or familial nonimmune nephropathy or amyloidosis is likely. Selected progressive cases despite standard care may justify an individualized therapeutic trial, with explicit uncertainty. [1]

The evidence underpinning glomerular immunosuppression remains substantially consensus-based. Serial proteinuria, renal function and albumin are used to assess effectiveness; glucocorticoids are not recommended as sole immunosuppressive therapy in the established-pathology recommendations. [4]

Include thrombotic risk and the next decision

IRIS recommends antithrombotic therapy for dogs with PLN and cautions that albumin, antithrombin, proteinuria and routine coagulation times do not reliably predict an individual dog's thrombotic risk. [2]

Document a thromboprophylaxis decision alongside bleeding concerns and planned procedures rather than waiting for a single laboratory trigger. At follow-up, decide whether to maintain supportive care, investigate a changing phenotype, revisit biopsy, or reassess a treatment trial. Keep disease progression, medication intolerance and a new intercurrent illness as separate possibilities.

Frequently Asked Questions

Does one increased UPC establish immune-mediated glomerular disease?

No. Proteinuria must be localized, and infection, inflammation, bleeding and overflow causes considered; UPC alone cannot establish an immune mechanism. [1]

Does normal creatinine exclude clinically important proteinuria?

No. IRIS includes investigation and treatment of persistent proteinuria in nonazotemic stage 1 dogs. [2]

Should every proteinuric dog undergo renal biopsy?

No. Biopsy is inappropriate when contraindications cannot be mitigated or the result will not change care; the consensus also advises against biopsy in stage 4 CKD. [1]

What makes biopsy useful before immunosuppression?

Specialized pathology can identify active immune-mediated injury and distinguish it from lesions unlikely to benefit; interpretation should integrate light, immunofluorescent and electron microscopy. [4]

Did telmisartan demonstrate a survival advantage over enalapril?

No. The randomized trial demonstrated a greater early reduction in proteinuria under the tested protocols; it did not establish a survival advantage. [3]

Can an ACE inhibitor or ARB be started in a dehydrated dog?

IRIS contraindicates their use during clinical dehydration or hypovolemia because glomerular filtration can fall precipitously. [2]

Can serum albumin alone determine thrombosis risk?

No. IRIS states that albumin, antithrombin and proteinuria poorly predict individual thrombotic risk. [2]